Interim Results for the six months ended 31 December 2011
Regenersis plc (LSE AIM: RGS) (“Regenersis” or the “Group”), a strategic outsourcing partner to many of the world’s leading consumer technology companies, is pleased to announce interim results for the six months ended 31 December 2011, which demonstrate good momentum in the business and reflect the strong progress already made in executing on the Group’s new strategy.
o Improved control of working capital
o First US trial for in-field diagnostic testers also secured
(*) Headline operating profit excludes exceptional restructuring costs, amortisation or impairment of acquired intangible assets, share-based payments and share of results of jointly controlled entities.
Regenersis’ Executive Chairman, Matthew Peacock, commented:
“The results of this first, full half year under the new board are pleasing. They demonstrate that our plans to deliver a step-up in operational and financial performance are beginning to take effect, driven by turnaround action in the underperforming UK business and by good contractual growth in Western Europe.
We have also made strong progress in establishing a solid platform for future growth. We have established new businesses in high growth markets such as Turkey and South Africa, signed a key multi-year contract to launch our in-field diagnostic tester, and acquired a new business in the Nordic market. Given this progress, the Board looks forward to the second half of the year and beyond with confidence.”
A full copy of the Interim Results can be found on our investor reports and presentations page.